2cji
From Proteopedia
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
| - | A series of novel, non-basic | + | A series of novel, non-basic 3-(6-chloronaphth-2-ylsulfonyl)aminopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating an alanylamide P4 group, was designed and synthesised. Within this series, the N-2-(morpholin-4-yl)-2-oxoethyl derivative 24 was shown to be a potent, selective fXa inhibitor with good anticoagulant activity. Moreover, 24 possessed highly encouraging rat and dog pharmacokinetic profiles with excellent oral bioavailabilities in both species. |
==Disease== | ==Disease== | ||
| Line 19: | Line 19: | ||
[[Category: Campbell, M.]] | [[Category: Campbell, M.]] | ||
[[Category: Chan, C.]] | [[Category: Chan, C.]] | ||
| - | [[Category: Convery, M | + | [[Category: Convery, M A.]] |
| - | [[Category: Hamblin, J | + | [[Category: Hamblin, J N.]] |
| - | [[Category: Kelly, H | + | [[Category: Kelly, H A.]] |
| - | [[Category: King, N | + | [[Category: King, N P.]] |
| - | [[Category: Mason, A | + | [[Category: Mason, A M.]] |
[[Category: Mitchell, C.]] | [[Category: Mitchell, C.]] | ||
| - | [[Category: Patel, V | + | [[Category: Patel, V K.]] |
[[Category: Senger, S.]] | [[Category: Senger, S.]] | ||
| - | [[Category: Shah, G | + | [[Category: Shah, G P.]] |
| - | [[Category: Watson, N | + | [[Category: Watson, N S.]] |
| - | [[Category: Weston, H | + | [[Category: Weston, H E.]] |
[[Category: Whitworth, C.]] | [[Category: Whitworth, C.]] | ||
| - | [[Category: Young, R | + | [[Category: Young, R J.]] |
[[Category: CA]] | [[Category: CA]] | ||
[[Category: GSK]] | [[Category: GSK]] | ||
| Line 46: | Line 46: | ||
[[Category: zymogen]] | [[Category: zymogen]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:49:17 2008'' |
Revision as of 14:49, 21 February 2008
|
CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
Contents |
Overview
A series of novel, non-basic 3-(6-chloronaphth-2-ylsulfonyl)aminopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating an alanylamide P4 group, was designed and synthesised. Within this series, the N-2-(morpholin-4-yl)-2-oxoethyl derivative 24 was shown to be a potent, selective fXa inhibitor with good anticoagulant activity. Moreover, 24 possessed highly encouraging rat and dog pharmacokinetic profiles with excellent oral bioavailabilities in both species.
Disease
Known disease associated with this structure: Factor X deficiency OMIM:[227600]
About this Structure
2CJI is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as Coagulation factor Xa, with EC number 3.4.21.6 Known structural/functional Site: . Full crystallographic information is available from OCA.
Reference
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors., Watson NS, Brown D, Campbell M, Chan C, Chaudry L, Convery MA, Fenwick R, Hamblin JN, Haslam C, Kelly HA, King NP, Kurtis CL, Leach AR, Manchee GR, Mason AM, Mitchell C, Patel C, Patel VK, Senger S, Shah GP, Weston HE, Whitworth C, Young RJ, Bioorg Med Chem Lett. 2006 Jul 15;16(14):3784-8. Epub 2006 May 11. PMID:16697194
Page seeded by OCA on Thu Feb 21 16:49:17 2008
Categories: Coagulation factor Xa | Homo sapiens | Single protein | Campbell, M. | Chan, C. | Convery, M A. | Hamblin, J N. | Kelly, H A. | King, N P. | Mason, A M. | Mitchell, C. | Patel, V K. | Senger, S. | Shah, G P. | Watson, N S. | Weston, H E. | Whitworth, C. | Young, R J. | CA | GSK | Blood coagulation | Calcium | Egf-like domain | Gamma-carboxyglutamic acid | Glycoprotein | Hydrolase | Hydroxylation | Polymorphism | Protease | Serine protease | Zymogen
